Hypothalamic peptides as drug targets for obesity

Current Opinion in Pharmacology

Volumn 1, Issue 6, 2001, Pages 651-655

  Dhillo, Waljit S ^a   Bloom, Stephen R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

A MSH; Agrp; CART; Endocannabinoids; Endocrinology; Ghrelin; GLP; MCH; Neuroscience; NPY; Obesity; Pharmacology

Indexed keywords

CANNABINOID; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RECEPTOR; GHRELIN; GLUCAGON LIKE PEPTIDE; GLUCAGON-LIKE-IMMUNOREACTIVITY; HYPOPHYSIS HORMONE; HYPOTHALAMUS HORMONE; MELANIN; MELANIN CONCENTRATING HORMONE; MELANIN-CONCENTRATING HORMONE; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; NERVE PROTEIN; NEUROPEPTIDE Y; PEPTIDE; PROOPIOMELANOCORTIN; PROTEIN; REV PROTEIN;

ANIMAL; DRUG POTENTIATION; EATING; ENERGY METABOLISM; GENETICS; HUMAN; HYPOTHALAMUS; METABOLISM; OBESITY; PHYSIOLOGY; REVIEW;

ANIMAL; CANNABINOIDS; EATING; ENERGY METABOLISM; HUMAN; HYPOTHALAMIC HORMONES; HYPOTHALAMUS; MELANINS; NERVE TISSUE PROTEINS; NEUROPEPTIDE Y; OBESITY; PEPTIDES; PITUITARY HORMONES; PRO-OPIOMELANOCORTIN; PROTEINS; RECEPTORS, CORTICOTROPIN;

EID: 0035654440     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00110-2     Document Type: Review

References (48)

1. Prescott-Clarke P., Primatesta P. Health Survey for England. 1996;1998 HMSO, London.
2. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 88:1997;131-141.
3. Yaswen L., Diehl N., Brennan M.B., Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med. 5:1999;1066-1070.
4. Graham M., Shutter J.R., Sarmiento U., Sarosi I., Stark K.L. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet. 17:1997;273-274.
5. Rossi M., Kim M.S., Morgan D.G., Small C.J., Edwards C.M., Sunter D., Abusnana S., Goldstone A.P., Russell S.H., Stanley S.A., et al. A C-terminal fragment of agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology. 139:1998;4428-4431.
6. Kim M.S., Rossi M., Abusnana S., Sunter D., Morgan D.G., Small C.J., Edwards C.M., Heath M.M., Stanley S.A., Seal L.J., et al. Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. Diabetes. 49:2000;177-182.
7. Krude H., Biebermann H., Luck W., Horn R., Brabant G., Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 19:1998;155-157.
8. Yeo G.S., Farooqi I.S., Aminian S., Halsall D.J., Stanhope R.G., O'Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet. 20:1998;111-112.
9. 4 receptor mutations occurs in extremely obese individuals.
10. Harrold J.A., Widdowson P.S., Williams G. Altered energy balance causes selective changes in melanocortin-4 (MC4-R), but not melanocortin-3 (MC3-R), receptors in specific hypothalamic regions: further evidence that activation of MC4-R is a physiological inhibitor of feeding. Diabetes. 48:1999;267-271.
11. Chen A.S., Metzger J.M., Trumbauer M.E., Guan X.M., Yu H., Frazier E.G., Marsh D.J., Forrest M.J., Gopal-Truter S., Fisher J., et al. Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res. 9:2000;145-154.
12. Kim M.S., Small C.J., Stanley S.A., Morgan D.G., Seal L.J., Kong W.M., Edwards C.M., Abusnana S., Sunter D., Ghatei M.A., Bloom S.R. The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J Clin Invest. 105:2000;1005-1011.
13. Small C.J., Kim M.S., Stanley S.A., Mitchell J.R., Murphy K., Morgan D.G., Ghatei M.A., Bloom S.R. Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes. 50:2001;248-254.
14. Fehm H.L., Smolnik R., Kern W., McGregor G.P., Bickel U., Born J. The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab. 86:2001;1144-1148.
15. Zarjevski N., Cusin I., Vettor R., Rohner-Jeanrenaud F., Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology. 133:1993;1753-1758.
16. Kalra S.P., Dube M.G., Sahu A., Phelps C.P., Kalra S. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA. 88:1991;10931-10935.
17. Duhault J., Boulanger M., Chamorro S., Boutin J.A., Della Z.O., Douillet E., Fauchere J.L., Feletou M., Germain M., Husson B., et al. Food intake regulation in rodents: Y5 or Y1 NPY receptors or both? Can J Physiol Pharmacol. 78:2000;173-185.
18. Hwa J.J., Witten M.B., Williams P., Ghibaudi L., Gao J., Salisbury B.G., Mullins D., Hamud F., Strader C.D., Parker E.M. Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am J Physiol. 277:1999;R1428-R1434.
19. Fekete C., Kelly J., Mihaly E., Sarkar S., Rand W.M., Legradi G., Emerson C.H., Lechan R.M. Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis. Endocrinology. 142:2001;2606-2613.
20. Naveilhan P., Hassani H., Canals J.M., Ekstrand A.J., Larefalk A., Chhajlani V., Arenas E., Gedda K., Svensson L., Thoren P., Ernfors P. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med. 5:1999;1188-1193.
21. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 402:1999;656-660.
22. Wren A.M., Small C.J., Ward H.L., Murphy K.G., Dakin C.L., Taheri S., Kennedy A.R., Roberts G.H., Morgan D.G., Ghatei M.A., Bloom S.R. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 141:2000;4325-4328.
23. Tschop M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature. 407:2000;908-913. The authors demonstrate that central administration of ghrelin causes an increase in food intake and body weight.
24. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., Matsukura S. A role for ghrelin in the central regulation of feeding. Nature. 409:2001;194-198.
25. Shintani M., Ogawa Y., Ebihara K., Aizawa-Abe M., Miyanaga F., Takaya K., Hayashi T., Inoue G., Hosoda K., Kojima M., et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 50:2001;227-232.
26. Kamegai J., Tamura H., Shimizu T., Ishii S., Sugihara H., Wakabayashi I. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology. 141:2000;4797-4800.
27. Tschop M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes. 50:2001;707-709. This is the first report that circulating ghrelin levels are decreased in human obesity.
28. Qu D., Ludwig D.S., Gammeltoft S., Piper M., Pelleymounter M.A., Cullen M.J., Mathes W.F., Przypek R., Kanarek R., Maratos-Flier E. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature. 380:1996;243-247.
29. Rossi M., Choi S.J., O'Shea D., Miyoshi T., Ghatei M.A., Bloom S.R. Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology. 138:1997;351-355.
30. Shimada M., Tritos N.A., Lowell B.B., Flier J.S., Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature. 396:1998;670-674.
31. Ludwig D.S., Tritos N.A., Mastaitis J.W., Kulkarni R., Kokkotou E., Elmquist J., Lowell B., Flier J.S., Maratos-Flier E. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest. 107:2001;379-386.
32. Kennedy A.R., Todd J.F., Stanley S.A., Abbott C.R., Small C.J., Ghatei M.A., Bloom S.R. Melanin-concentrating hormone (MCH) suppresses thyroid stimulating hormone (TSH) release, in vivo and in vitro, via the hypothalamus and the pituitary. Endocrinology. 142:2001;3265-3268.
33. Chambers J., Ames R.S., Bergsma D., Muir A., Fitzgerald L.R., Hervieu G., Dytko G.M., Foley J.J., Martin J., Liu W.S., et al. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature. 400:1999;261-265.
34. Mori M., Harada M., Terao Y., Sugo T., Watanabe T., Shimomura Y., Abe M., Shintani Y., Onda H., Nishimura O., Fujino M. Cloning of a novel G protein-coupled receptor, SLT, a subtype of the melanin-concentrating hormone receptor. Biochem Biophys Res Commun. 283:2001;1013-1018. This is the first report of the identification of a second MCH receptor.
35. Williams C.M., Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology. 143:1999;315-317.
36. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63:1998;L113-L117.
37. Di Marzo V.V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 410:2001;822-825. This report demonstrates that endogenous cannabinoids may be involved in maintaining food intake in mice made hyperphagic by brief food deprivation.
38. Kristensen P., Judge M.E., Thim L., Ribel U., Christjansen K.N., Wulff B.S., Clausen J.T., Jensen P.B., Madsen O.D., Vrang N., et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature. 393:1998;72-76.
39. Lambert P.D., Couceyro P.R., McGirr K.M., Dall Vechia S.E., Smith Y., Kuhar M.J. CART peptides in the central control of feeding and interactions with neuropeptide Y. Synapse. 29:1998;293-298.
40. Vrang N., Tang-Christensen M., Larsen P.J., Kristensen P. Recombinant CART peptide induces c-Fos expression in central areas involved in control of feeding behaviour. Brain Res. 818:1999;499-509.
41. Abbott C.R., Rossi M., Wren A.M., Murphy K.G., Kennedy A.R., Stanley S.A., Zollner A.N., Morgan D.G., Morgan I., Ghatei M.A., et al. Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript (CART) following administration into discrete hypothalamic nuclei. Endocrinology. 142:2001;3457-3463.
42. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 379:1996;69-72.
43. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 2:1996;1254-1258.
44. Edwards C.M., Todd J.F., Mahmoudi M., Wang Z., Wang R.M., Ghatei M.A., Bloom S.R. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 48:1999;86-93.
45. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., Winterhalder R., Conen D., Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 44:1999;81-86.
46. Tang-Christensen M., Larsen P.J., Thulesen J., Romer J., Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med. 6:2000;802-807. This is the first report of the anorectic effects of GLP-2.
47. Dakin CL, Gunn I, Small CJ, Edwards CMB, Hay DL, Smith DM, Ghatei MA, Bloom SR: Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001, in press.
48. 4 receptor to physiologically modulate feeding behaviour.